Professor, Psychiatry, UCLA School of Medicine
Psychiatry
Dr. Guochuan E. Tsai, MD
|
|
Give Review
Guochuan Tsai is an expert in the field of Psychiatry. He attended National Yang Ming University Medical College. Guochuan Tsai is a published doctor and has 76 publications published. The lastest was: 'Ca2+-independent myosin II phosphorylation and contraction in chicken embryo fibroblasts.' Guochuan Tsai accepts Medicare payments and is registered with Medicare.gov.
Publications
- Assessing the Construct Validity of the Chinese-Version Schizotypal Personality Questionnaire-Brief on Male and Female Undergraduate Students.
- Impact of dietary benzoic Acid on treatment response in Schizophrenia-reply.
- Nuclear receptor TLX stimulates hippocampal neurogenesis and enhances learning and memory in a transgenic mouse model.
- Regulating the CNS Grand Regulators; N-methyl-D-aspartate Receptor-Mediated Neurotransmission.
- NMDA Neurotransmission Dysfunction in Mild Cognitive Impairment and Alzheimer's Disease.
- Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation.
- Clinical and cerebral volumetric effects of sodium benzoate, a D-amino acid oxidase inhibitor, in a drug-naïve patient with Major depression.
- Clozapine protects bone mineral density in female patients with Schizophrenia.
- Sarcosine therapy for obsessive compulsive Disorder: a prospective, open-label study.
- Glutamate signaling in the pathophysiology and therapy of Schizophrenia.
- Disposition of D-serine in healthy adults.
- RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with Schizophrenia.
- Sarcosine (N-methylglycine) treatment for acute Schizophrenia: a randomized, double-blind study.
- Searching for rational anti N-methyl-D-aspartate treatment for depression.
- Low cerebrospinal fluid glutamate and glycine in refractory affective Disorder.
- D-alanine added to antipsychotics for the treatment of Schizophrenia.
- Sarcosine or D-serine add-on treatment for acute exacerbation of Schizophrenia: a randomized, double-blind, placebo-controlled study.
- A case series of D-cycloserine added to donepezil in the treatment of Alzheimer's disease.
- Central nervous pathway for acupuncture stimulation: localization of processing with functional MR imaging of the brain--preliminary experience.
- Ca2+-independent myosin II phosphorylation and contraction in chicken embryo fibroblasts.
- [Dependence of the topography of the hepatic veins on the external shape of the liver, its size and on age].
- A glutamatergic model of ECT-induced memory dysfunction.
- Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (NAAG) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (NAALADase).
- Rat brain N-acetylated alpha-linked acidic dipeptidase activity. Purification and immunologic characterization.
- Calcium-dependent evoked release of N-[3H]acetylaspartylglutamate from the optic pathway.
- The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo.
- Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II.
- Neuroleptic malignant syndrome associated with clozapine treatment.
- N-acetylaspartate in neuropsychiatric Disorders.
- Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis.
- The glutamatergic basis of human alcoholism.
- Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
- Functional magnetic resonance imaging of personality switches in a woman with dissociative identity Disorder.
- Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo.
- A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in Schizophrenia patients.
- Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants.
- Tardive dyskinesia and substrates of energy metabolism in CSF.
- Glutamatergic neurotransmission in alcoholism.
- Elevated cerebrospinal fluid SNAP-25 in Schizophrenia.
- Ionotropic glutamate receptors as therapeutic targets in Schizophrenia.
- Reduced glycine transporter type 1 expression leads to Major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice.
- The role of glutamatergic neurotransmission in the pathophysiology of alcoholism.
- The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the mouse retina.
- Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and Schizophrenia.
- Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways.
- Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.
- Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal.
- Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease.
- Gene knockout of glycine transporter 1: characterization of the behavioral phenotype.
- D-cycloserine added to clozapine for patients with Schizophrenia.
- Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in Schizophrenia.
- Promoter analysis of human glutamate carboxypeptidase II.
- Association between serotonin transporter gene promoter polymorphism and suicide: results of a meta-analysis.
- Glutamatergic neurotransmission involves structural and clinical deficits of Schizophrenia.
- Converging evidence of NMDA receptor hypofunction in the pathophysiology of Schizophrenia.
- NMDA receptor function, neuroplasticity, and the pathophysiology of Schizophrenia.
- Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.
- Glutamatergic mechanisms in Schizophrenia.
- D-serine added to clozapine for the treatment of Schizophrenia.
- The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in Schizophrenia.
- Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment.
- A preliminary study of D-cycloserine treatment in Alzheimer's disease.
- Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior.
- A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with Schizophrenia.
- D-serine added to antipsychotics for the treatment of Schizophrenia.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of Schizophrenia.
- Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of Schizophrenia.
- Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice.
- Emotional management and 5-HT2A receptor gene variance in patients with Schizophrenia.
- Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in Schizophrenia, a critical review and meta-analysis.
- Novel therapies for Schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission.
- A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for Schizophrenia.
- Reliability and validity of three Chinese-version tasks of Mayer-Salovey-Caruso Emotional Intelligence Test.
- NMDA neurotransmission as a critical mediator of borderline personality Disorder.
- Assessing gene-gene interactions in pharmacogenomics.
Schools
National YangMing College Of Medicine
Procedures Preformed
- Psychiatric Evaluation
Conditions Treated
- Major Depressive Disorder
- Schizophrenia
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
Massachusetts General Hospital -
National Yang Ming University Medical College
Drug Facts
| NPI NUMBER | 1447207816 | |
| NPPES Provider LastName | TSAI | |
| NPPES Provider FirstName | GUOCHUAN | |
| NPPES Provider ZIPCode | 905022004 | |
| NPPES Provider State | CA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 2018.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447207816 |
| Last Name Of The Provider | TSAI |
| First Name Of The Provider | GUOCHUAN |
| View All |
Similar Doctors
|
|
Dr. Denise Bridgeford, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jim S. Chomchai, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mihai A. Chituc, MD |
|
|
Dr. Moiez Khankhanian, MD |
|
|
Dr. Dayalal D. Tank, MD
This Doctor is OpenDoctor Recommended.
|